Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease

C.J. van der Woude; P. Stokkers; A.A. van Bodegraven; G. Van Assche; Z. Hebzda; L. Paradowski; G d'Haens; S. Ghosh; B. Feagan; P. Rutgeerts; G. Dijkstra; D.J. Jong; B. Oldenburg; M. Farhan; T. Richard; Y. Dean; D.W. Hommes

doi:10.1002/ibd.21252

Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease

C.J. van der Woude, P. Stokkers, A.A. van Bodegraven, G. Van Assche, Z. Hebzda, L. Paradowski, G d'Haens, S. Ghosh, B. Feagan, P. Rutgeerts, G. Dijkstra, D.J. Jong, B. Oldenburg, M. Farhan, T. Richard, Y. Dean, D.W. Hommes

Gastroenterology and hepatology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1708-1716
Journal	Inflammatory Bowel Diseases
Volume	16
Issue number	10
DOIs	https://doi.org/10.1002/ibd.21252
Publication status	Published - 2010

Access to Document

10.1002/ibd.21252

Cite this

van der Woude, C. J., Stokkers, P., van Bodegraven, A. A., Van Assche, G., Hebzda, Z., Paradowski, L., d'Haens, G., Ghosh, S., Feagan, B., Rutgeerts, P., Dijkstra, G., Jong, D. J., Oldenburg, B., Farhan, M., Richard, T., Dean, Y., & Hommes, D. W. (2010). Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease. Inflammatory Bowel Diseases, 16(10), 1708-1716. https://doi.org/10.1002/ibd.21252

van der Woude, C.J. ; Stokkers, P. ; van Bodegraven, A.A. ; Van Assche, G. ; Hebzda, Z. ; Paradowski, L. ; d'Haens, G ; Ghosh, S. ; Feagan, B. ; Rutgeerts, P. ; Dijkstra, G. ; Jong, D.J. ; Oldenburg, B. ; Farhan, M. ; Richard, T. ; Dean, Y. ; Hommes, D.W. / Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease. In: Inflammatory Bowel Diseases. 2010 ; Vol. 16, No. 10. pp. 1708-1716.

@article{b044bd4027f24458959e4467f461e45b,

title = "Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease",

author = "{van der Woude}, C.J. and P. Stokkers and {van Bodegraven}, A.A. and {Van Assche}, G. and Z. Hebzda and L. Paradowski and G d'Haens and S. Ghosh and B. Feagan and P. Rutgeerts and G. Dijkstra and D.J. Jong and B. Oldenburg and M. Farhan and T. Richard and Y. Dean and D.W. Hommes",

year = "2010",

doi = "10.1002/ibd.21252",

language = "Undefined/Unknown",

volume = "16",

pages = "1708--1716",

journal = "Inflammatory Bowel Diseases",

issn = "1078-0998",

publisher = "John Wiley and Sons Inc.",

number = "10",

}

van der Woude, CJ, Stokkers, P, van Bodegraven, AA, Van Assche, G, Hebzda, Z, Paradowski, L, d'Haens, G, Ghosh, S, Feagan, B, Rutgeerts, P, Dijkstra, G, Jong, DJ, Oldenburg, B, Farhan, M, Richard, T, Dean, Y & Hommes, DW 2010, 'Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease', Inflammatory Bowel Diseases, vol. 16, no. 10, pp. 1708-1716. https://doi.org/10.1002/ibd.21252

Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease. / van der Woude, C.J.; Stokkers, P.; van Bodegraven, A.A.; Van Assche, G.; Hebzda, Z.; Paradowski, L.; d'Haens, G; Ghosh, S.; Feagan, B.; Rutgeerts, P.; Dijkstra, G.; Jong, D.J.; Oldenburg, B.; Farhan, M.; Richard, T.; Dean, Y.; Hommes, D.W.

In: Inflammatory Bowel Diseases, Vol. 16, No. 10, 2010, p. 1708-1716.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease

AU - van der Woude, C.J.

AU - Stokkers, P.

AU - van Bodegraven, A.A.

AU - Van Assche, G.

AU - Hebzda, Z.

AU - Paradowski, L.

AU - d'Haens, G

AU - Ghosh, S.

AU - Feagan, B.

AU - Rutgeerts, P.

AU - Dijkstra, G.

AU - Jong, D.J.

AU - Oldenburg, B.

AU - Farhan, M.

AU - Richard, T.

AU - Dean, Y.

AU - Hommes, D.W.

PY - 2010

Y1 - 2010

U2 - 10.1002/ibd.21252

DO - 10.1002/ibd.21252

M3 - Article

C2 - 20848453

VL - 16

SP - 1708

EP - 1716

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 10

ER -

van der Woude CJ, Stokkers P, van Bodegraven AA, Van Assche G, Hebzda Z, Paradowski L et al. Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease. Inflammatory Bowel Diseases. 2010;16(10):1708-1716. https://doi.org/10.1002/ibd.21252